Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052839 · ClinicalTrials.gov registry record · Phase 2
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
A Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), sponsored by Dan Zandberg.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06052839: Recruiting Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), sponsored by Dan Zandberg.
NCT06052839 is a Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) that is actively recruiting participants, run by Dan Zandberg. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06052839, a Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), is actively recruiting participants, sponsored by Dan Zandberg.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb) therapy and that chemotherapy given after anti-PD-1 mAb therapy is associated with higher efficacy.
Primary Outcome
Proportion of patients alive and without disease progression at 6 months after starting treatment, per RECIST v1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also conside
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06052839 shows while recruiting
NCT06052839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06052839 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06052839 about?
NCT06052839 is a clinical study titled "Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC". The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb...
What is the current status of trial NCT06052839?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-10-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06052839 study?
This clinical trial studies the following conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC).
What interventions are being tested in trial NCT06052839?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06052839?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052839 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06052839's enrollment target sits among peer trials
15 1920th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI